Enhancing the dissolution rate of poorly soluble drug Febuxostat using spray dried amorphous solid dispersion technique

被引:0
作者
Patel, Vaishali [1 ]
Patel, Anita [2 ]
Shah, Ashish [3 ]
机构
[1] Laxminarayandev Coll Pharm, Dept Pharmaceut, Bharuch, Gujarat, India
[2] Sankalchand Patel Univ, Nootan Pharm Coll, Dept Pharmaceut, Visnagar, Gujarat, India
[3] Sumandeep Vidyapeeth, Dept Pharm, Vadodara, Gujarat, India
关键词
Febuxostat; Amorphous Solid dispersion; Kollidon SR; HPMC K4M; Full factorial design; FORMULATION; RELEASE; HYDROCHLORIDE; OPTIMIZATION; DESIGN;
D O I
10.30827/ars.v64i2.27058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Febuxostat belongs to Biopharmaceutical classification system (BCS) class II drugs, which have low solubility and high permeability. Amorphous solid dispersion is one of the techniques which can be useful to improve solubility and powder characteristics. Objective: To optimize the concentration of hydrophilic and hydrophobic polymers to improve the dissolution rate and solubility of febuxostat tablets. Methods: The amorphous solid dispersion of febuxostat was prepared by spray drying method using Kolliphor P237 (1:2). This amorphous solid dispersion was further used to compress the tablet. To improve solubility and dissolution rate, a full factorial design was applied to optimize the critical concentration of Kollidon SR and hydroxypropyl methyl cellulose (HPMC K4M). The prepared tablets were characterized by pre-compression and post-compression parameters. Result: The rate of drug release was sustained by formulating an amorphous solid dispersion technique. The optimized batch (FSRT-OB) was found to be fit for release average 93.30 % of the drug in sustain release manner up to 12hrs. The release kinetic data suggests that the drug release was controlled by combination of diffusion and chain relaxation mechanism. The optimized concentration for Kollidon SR and HPMC K4Mwas found to be 38.50 % and 7.72 % respectively. Conclusion: Amorphous solid dispersion technique is useful to enhance solubility, dissolution rate, and bioavailability of the Febuxostat tablet.
引用
收藏
页码:123 / 138
页数:16
相关论文
共 20 条
[1]   Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension [J].
Ahuja, Bhupesh K. ;
Jena, Sunil K. ;
Paidi, Sharan K. ;
Bagri, Surbhi ;
Suresh, Sarasija .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 478 (02) :540-552
[2]  
[Anonymous], 2014, Indo Amer. J. Pharm. Res.
[3]   Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout [J].
Bisht, Manisha ;
Bist, S. S. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 73 (06) :597-600
[4]   PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION SYSTEMS [J].
CHIOU, WL ;
RIEGELMAN, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (09) :1281-+
[5]  
Eriksson L., 2008, Design of Experiments-Principles and Applications
[6]  
Habib W, 2000, CRIT REV THER DRUG, V17, P61, DOI 10.1615/CritRevTherDrugCarrierSyst.v17.i1.20
[7]   Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique [J].
Jung, JY ;
Yoo, SD ;
Lee, SH ;
Kim, KH ;
Yoon, DS ;
Lee, KH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 187 (02) :209-218
[8]   Characterization of curcumin-PVP solid dispersion obtained by spray drying [J].
Paradkar, A ;
Ambike, AA ;
Jadhav, BK ;
Mahadik, KR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) :281-286
[9]   Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis [J].
Patel, Jaydeep ;
Dhingani, Anjali ;
Garala, Kevin ;
Raval, Mihir ;
Sheth, Navin .
POWDER TECHNOLOGY, 2014, 258 :331-343
[10]   Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study [J].
Saag, Kenneth G. ;
Becker, Michael A. ;
Whelton, Andrew ;
Hunt, Barbara ;
Castillo, Majin ;
Kisfalvi, Krisztina ;
Gunawardhana, Lhanoo .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (01) :143-153